Study to investigate if the uptake of Ticagrelor into the body differs depending on method of administration.

Study identifier:D5130C00076

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open-label, randomised, 3-period, 3-treatment, crossover, single-centre, single-dose, bioavailability study with alternative methods of administration of crushed ticagrelor tablets, 90 mg, compared to whole ticagrelor tablets, 90 mg, in healthy volunteer

Medical condition

Bioavailability Heathy volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Ticagrelor 90 mg whole tablet, Ticagrelor 90 mg tablet crushed, Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube

Sex

All

Actual Enrollment

36

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 01 Jul 2013
Primary Completion Date: 01 Sept 2013
Study Completion Date: 01 Sept 2013

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Dec 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria